| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 05/09/2006 | US7041478 Polypeptide for use in the treatment cancer, inflammation of autoimmune disorders |
| 05/09/2006 | US7041475 Transport protein for use in human therapeutics and diagnostics |
| 05/09/2006 | US7041461 Nucleotide sequences coding membrame protein for use in analgesics |
| 05/09/2006 | US7041460 Antibodies to monocyte-colony inhibitory factor (M-CIF) |
| 05/09/2006 | US7041454 Genomic sequence of the purH gene and purH-related biallelic markers |
| 05/09/2006 | US7041449 Determination of age in animals; obtain tissue sample from animal, monitor expression pattern of marker gene, compare to expression pattern in younger control, evaluate sample for aging |
| 05/09/2006 | US7041440 IP3-binding polypeptides and methods of using them |
| 05/09/2006 | US7041437 Genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions. |
| 05/09/2006 | US7041300 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines |
| 05/09/2006 | US7041297 Tumor antigen peptides originating in cyclophilin B |
| 05/09/2006 | US7041295 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 05/09/2006 | US7041291 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 05/09/2006 | US7041284 Recombinant adenoviral vector and method of use |
| 05/09/2006 | US7041282 Ligands for flt3 receptors |
| 05/09/2006 | CA2175687C A bacterial nitroreductase gene-prodrug system |
| 05/04/2006 | WO2006047759A2 Kinase inhibitors for the treatment of diabetes and obesity |
| 05/04/2006 | WO2006047687A2 Compositions and methods for short interfering nucleic acid inhibition of nav1.8 |
| 05/04/2006 | WO2006047683A2 Antisense antiviral compound and method for treating influenza viral infection |
| 05/04/2006 | WO2006047638A2 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 05/04/2006 | WO2006047394A1 Therapeutic rnai agents for treating psoriasis |
| 05/04/2006 | WO2006047301A2 Parvovirus methods and compositions for killing neoplastic cells |
| 05/04/2006 | WO2006047172A1 Tweak receptor |
| 05/04/2006 | WO2006046766A1 Gene therapy for treatment of cardiac failure |
| 05/04/2006 | WO2006046243A1 Sv40 for gene therapy of renal disorders |
| 05/04/2006 | WO2006046017A2 Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter |
| 05/04/2006 | WO2006045202A1 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
| 05/04/2006 | WO2006021894A3 Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| 05/04/2006 | WO2006005461A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27) |
| 05/04/2006 | WO2006000719A3 COG47 PROTEIN AND S100β GENE POLYMORPHISM |
| 05/04/2006 | WO2005117974A3 Cancer treatment method by inhibiting mage gene expression or function |
| 05/04/2006 | WO2005117950A3 Regulation of glucose and insulin levels by gnt-4 glycosyltransferase activity |
| 05/04/2006 | WO2005116224A3 Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| 05/04/2006 | WO2005113016A3 Modulation of glucose-6-phosphatase translocase expression |
| 05/04/2006 | WO2005109002A3 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 05/04/2006 | WO2005089398A3 Method for the delivery of sustained release agents |
| 05/04/2006 | WO2005033285A3 GENE MODULATION BY RB2/p130 EXPRESSION |
| 05/04/2006 | WO2004037972A3 Endogenous retrovirus up-regulated in prostate cancer |
| 05/04/2006 | US20060095984 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 05/04/2006 | US20060094684 Co-administering the vector with rapamycin; antibodies that block B7-1 & 2, CD28 or CD40L; transgene encodes glucocerebrosidase, alpha-galactosidase A, beta-galactosidase, sphingomyelinase, iduronate sulfatase, alpha-glucosidase, alpha-iduronidase, Factor VIIA, Factor VIII or Factor IX. |
| 05/04/2006 | US20060094683 Immunomodulatory oligonucleotides |
| 05/04/2006 | US20060094682 administering a protein tyrosine kinase inhibitor such as bosutinib, or pyrido(2,3-d)pyrimidine drug known as PD 161570; drug screening; bioassays |
| 05/04/2006 | US20060094681 Immunostimulatory oligonucleotide multimers |
| 05/04/2006 | US20060094679 Method of preventing or treating liver disease |
| 05/04/2006 | US20060094678 Drug delivery of nucleotide into tumor; antitumor biodrugs; stability in cells; prevent gene expression of target genes |
| 05/04/2006 | US20060094677 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNA as anti-inflammatory therapeutics |
| 05/04/2006 | US20060094676 Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 05/04/2006 | US20060094675 Method for the repair of mutated RNA from genetically defective DNA and for the specific destruction of tumor cells by RNA trans-splicing, and a method for the detection of naturally trans-spliced cellular RNA |
| 05/04/2006 | US20060094674 Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| 05/04/2006 | US20060094673 Polymer surfactants for gene therapy applications |
| 05/04/2006 | US20060094657 Inhibiting development of microvessels within coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy |
| 05/04/2006 | US20060094111 DNA containing variant FRT sequences |
| 05/04/2006 | US20060094061 Drug screening for inhibititors of extracellular matrix (ECM) degradation and inflammation using polypeptide and fragments, expression inhibitory agents such as antisense polynucleotide, a ribozyme, and a small interfering RNA; measuring binding affinity; arthritis; matrix metalloprotease, cathepsin |
| 05/04/2006 | US20060094055 RNA silencing in animals as an antiviral defense |
| 05/04/2006 | US20060094054 Fibulin-3 and uses thereof |
| 05/04/2006 | US20060094043 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 05/04/2006 | US20060094032 iRNA agents targeting VEGF |
| 05/04/2006 | US20060093674 Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
| 05/04/2006 | US20060093653 Periadventitial delivery device |
| 05/04/2006 | US20060093625 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and an orphanin polypeptide as a targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction |
| 05/04/2006 | US20060093610 Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS 06 of pseudomonas aeruginosa |
| 05/04/2006 | US20060093607 treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth |
| 05/04/2006 | US20060093606 Compositions and methods of using angiopoietin-like 4 protein |
| 05/04/2006 | US20060093604 Method of treatment and prophylaxis |
| 05/04/2006 | US20060093603 ErbB4 antagonists |
| 05/04/2006 | US20060093600 Antibodies to CD40 |
| 05/04/2006 | US20060093590 Pseudotyped retroviruses |
| 05/04/2006 | US20060093589 Vp2-modified raav vector compositions and uses therefor |
| 05/04/2006 | US20060093587 Transplants for myocardial scars |
| 05/04/2006 | US20060093585 Providing mammalian cell contacted with agent and adeno-associated virus (AAV), identifying agent that when contacted with mammalian cell enhances AAV transduction after viral binding to membrane of contacted mammalian cell and before second strand synthesis which yields expressible form of viral genome |
| 05/04/2006 | US20060093584 Intravascular delivery of nucleic acid |
| 05/04/2006 | US20060093583 Targeted infusion of agents against Parkinson's disease |
| 05/04/2006 | US20060093582 Listeria-based and LLO-based vaccines |
| 05/04/2006 | US20060093574 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 05/04/2006 | US20060093557 Particulate composition |
| 05/04/2006 | US20060093553 Cd26-based therapies for cancers and immune disease |
| 05/04/2006 | CA2592351A1 Transcriptional inhibitor for human k-ras gene |
| 05/04/2006 | CA2586019A1 Kinase inhibitors for the treatment of diabetes and obesity |
| 05/04/2006 | CA2585703A1 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 05/04/2006 | CA2585354A1 Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter |
| 05/04/2006 | CA2584986A1 Use of apoptosis inhibiting compounds in degenerative neurological disorders |
| 05/04/2006 | CA2584785A1 Compositions and methods for short interfering nucleic acid inhibition of nav1.8 |
| 05/04/2006 | CA2584489A1 Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
| 05/04/2006 | CA2583826A1 Therapeutic rnai agents for treating psoriasis |
| 05/04/2006 | CA2583677A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain |
| 05/04/2006 | CA2582143A1 Gene therapy for treatment of heart failure |
| 05/03/2006 | EP1652936A2 cDNA for human methylenetetrahydrofolate reductase |
| 05/03/2006 | EP1652932A1 Method for the generation of virus producing cell lines and cell lines |
| 05/03/2006 | EP1652931A2 Recombinant adenoviruses, preparation and uses thereof for the treatment and/or prevention ofs cancers |
| 05/03/2006 | EP1652917A1 Rna capable of inhibiting expression of klf5 gene |
| 05/03/2006 | EP1651956A2 Melks as modifiers of the rac pathway and methods of use |
| 05/03/2006 | EP1651752A2 Methods of inhibiting cancer growth by binding to nuclear receptors |
| 05/03/2006 | EP1651667A1 Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
| 05/03/2006 | EP1651254A1 Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1-antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds |
| 05/03/2006 | EP1651250A1 Use of human growth hormone in multiple system atrophy |
| 05/03/2006 | EP1651247A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 05/03/2006 | EP1651239A1 Intravascular delivery of non-viral nucleic acid |
| 05/03/2006 | EP1651050A1 Acellular tissue matrices made from galactose alpha-1,3-galactose -deficient tissue |
| 05/03/2006 | EP1425046A4 Wild-type ras as a cancer therapeutic agent |
| 05/03/2006 | EP1317273B1 Use of il-6r/il-6 chimera in huntington's disease |
| 05/03/2006 | EP1189611B1 Cancer therapy |